Association Between Early Recurrence and Long-Term Recurrence After Pulsed Field Ablation for Atrial Fibrillation: Prospective Real-World Evidence From China

Condition(s) studied

Investigational drug(s) / intervention(s)

pulsed field ablation: The patient underwent the ablation procedure using the pentaspline pulsed field ablation system.

Study summary

The goal of this observational study is to analyze the predictive value of early recurrence within different time windows for late recurrence, ultimately providing evidence-based support for defining the blanking period after pulsed field ablation and stratifying recurrence risk, with the goal of transforming clinical management strategies following pulsed field ablation. The main questions it aims to answer are:

1. Employ big data analysis methods to develop a risk stratification tool for atrial fibrillation;
2. Identify high-risk prognostic indicators for atrial fibrillation and establish early assessment models for short-term and long-term prognosis.

Participants will undergo pulsed field ablation for the treatment of atrial fibrillation and will receive structured follow-ups at 1, 3, 6, and 12 months post-ablation. At each follow-up, a 24-hour Holter monitor will be performed to systematically assess the recurrence of atrial arrhythmias and the atrial arrhythmia burden.

Eligibility

Primary outcome measure(s)

• Atrial arrhythmias — from 3 months to 12 months post-ablation
  Including atrial fibrillation, atrial flutter, and atrial tachycardia, recorded as ≥10 seconds on a 12-lead electrocardiogram or ≥30 seconds on ambulatory electrocardiography (including single-lead patch devices).

Trial sites (1)

More West China Hospital trials in China

Other trials for the same condition